Abstract: This disclosure relates to a method of generating a symbol string based on an input sentence represented by a sequence of symbols. In particular, the method involves receiving an input symbol string representing a sentence, generating, using a neural network based on a sequence of dependency structure of elements in the input symbol string, an output symbol string corresponding to the input sentence. The neural network includes an encoder that converts elements of the input symbol string to a first hidden state in a form of a multi-dimensional vector, an attention mechanism that applies a weight to the first hidden state and generates the weighted first hidden state as a second hidden state, a decoder that generates a third hidden state based on at least one element of the input symbol string, an element of the output symbol string, and the second hidden state, and an output generator that generates an element of the output symbol string based on the second hidden state and the third hidden state.

Abstract: A charging base includes: a base seat installed on a floor surface; a columnar tower part provided on the base seat; a first support provided on the tower part and capable of supporting a vertical first electric vacuum cleaner; and a second support provided on the tower part and capable of supporting a vertical second electric vacuum cleaner. An electric vacuum cleaner system includes the charging base configured as described above, the vertical first electric vacuum cleaner, and the vertical second electric vacuum cleaner.

Abstract: An assembling method includes fitting an entire range of the guide portion to the stem section with a gap therebetween, and inserting a bolt from an outboard side through a bolt insertion hole formed in the hub wheel. In this state, a maximum inclination angle of the bolt with respect to the hub wheel is set to be larger than a maximum inclination angle of the outer joint member with respect to the hub wheel. The method also includes connecting the bearing and the constant velocity universal joint to each other by threadedly engaging and fastening the bolt into a bolt hole formed in the stem section.

Abstract: A bearing device for a wheel has a wheel bearing including inner and outer rings, a hub wheel, and balls between outer raceway surfaces of the outer ring and inner raceway surfaces of the hub wheel and the inner ring. A stem section is fitted into an inner diameter of the hub wheel to couple a constant velocity universal joint to the wheel bearing through a screw fastening structure so that a shoulder portion of an outer joint member abuts against a crimped portion of the hub wheel. Projecting portions formed on the stem section are press-fitted into the hub wheel having depressed portions formed to interfere with the projecting portions, and a shape of the projecting portions is transferred to the hub wheel providing a projection and depression fitting structure in which the projecting and depressed portions are in close contact at an entire fitting contact portion therebetween.

Abstract: A compound represented by the following general formula (I) or a pharmacologically acceptable salt thereof, wherein R1 represents a C1 to C6 alkyl group which may be substituted by one to three groups selected from substituent group A, or the like (substituent group A: a hydroxy group, a halogeno group, a cyano group, a nitro group, an amino group, a carboxy group, a C1 to C3 alkyl group, etc.); R2, R3, and R8 each independently represent a hydrogen atom or a C1 to C3 alkyl group; R4, R5, R6, R7, R9, and R10 each independently represent a hydrogen atom or the like; and R11 represents a hydrogen atom or the like, has TAFIa enzyme inhibitory activity and is useful as a therapeutic drug for myocardial infarction, angina pectoris, acute coronary syndrome, cerebral infarction, deep vein thrombosis, pulmonary embolism, or the like.

Abstract: An assembling method includes fitting an entire range of the guide portion to the stem section with a gap therebetween, and inserting a bolt from an outboard side through a bolt insertion hole formed in the hub wheel. In this state, a maximum inclination angle of the bolt with respect to the hub wheel is set to be larger than a maximum inclination angle of the outer joint member with respect to the hub wheel. The method also includes connecting the bearing and the constant velocity universal joint to each other by threadedly engaging and fastening the bolt into a bolt hole formed in the stem section.

Abstract: A compound represented by the following general formula (I) or a pharmacologically acceptable salt thereof, wherein A represents a C3 to C12 cycloalkyl group which may be substituted by one to three selected from a fluoro group, a hydroxy group, a C1 to C6 alkyl group, etc; R1, R2, and R3 each independently represent a hydrogen atom, a fluoro group, or a C1 to C6 alkyl group; R4 represents a hydrogen atom or a prodrug group; and Y represents —CH2—CHR5—CH2—NHR6 (wherein R5 represents a hydrogen atom, a C1 to C6 alkyl group, or a C1 to C6 alkoxy group, and R6 represents a hydrogen atom or a prodrug group), or the like exhibits excellent TAFIa inhibitory activity and is useful as a therapeutic drug for myocardial infarction, angina pectoris, acute coronary syndrome, cerebral infarction, deep vein thrombosis, pulmonary embolism, and the like.

Abstract: A bearing device for a wheel has a wheel bearing including inner and outer rings, a hub wheel, and balls between outer raceway surfaces of the outer ring and inner raceway surfaces of the hub wheel and the inner ring. A stem section is fitted into an inner diameter of the hub wheel to couple a constant velocity universal joint to the wheel bearing through a screw fastening structure so that a shoulder portion of an outer joint member abuts against a crimped portion of the hub wheel. Projecting portions formed on the stem section are press-fitted into the hub wheel having depressed portions formed to interfere with the projecting portions, and a shape of the projecting portions is transferred to the hub wheel providing a projection and depression fitting structure in which the projecting and depressed portions are in close contact at an entire fitting contact portion therebetween.

Abstract: A compound represented by the following general formula (I) or a pharmacologically acceptable salt thereof, wherein R1 represents a C1 to C6 alkyl group which may be substituted by one to three groups selected from substituent group A, or the like (substituent group A: a hydroxy group, a halogeno group, a cyano group, a nitro group, an amino group, a carboxy group, a C1 to C3 alkyl group, etc.); R2, R3, and R8 each independently represent a hydrogen atom or a C1 to C3 alkyl group; R4, R5, R6, R7, R9, and R10 each independently represent a hydrogen atom or the like; and R11 represents a hydrogen atom or the like, has TAFIa enzyme inhibitory activity and is useful as a therapeutic drug for myocardial infarction, angina pectoris, acute coronary syndrome, cerebral infarction, deep vein thrombosis, pulmonary embolism, or the like.

Abstract: A compound represented by the following general formula (I) or a pharmacologically acceptable salt thereof, wherein R1 represents a C1 to C6 alkyl group which may be substituted by one to three groups selected from substituent group A, or the like (substituent group A: a hydroxy group, a halogeno group, a cyano group, a nitro group, an amino group, a carboxy group, a C1 to C3 alkyl group, etc.); R2, R3, and R8 each independently represent a hydrogen atom or a C1 to C3 alkyl group; R4, R5, R6, R7, R9, and R10 each independently represent a hydrogen atom or the like; and R11 represents a hydrogen atom or the like, has TAFIa enzyme inhibitory activity and is useful as a therapeutic drug for myocardial infarction, angina pectoris, acute coronary syndrome, cerebral infarction, deep vein thrombosis, pulmonary embolism, or the like.

Abstract: A compound represented by the following general formula (I) or a pharmacologically acceptable salt thereof, wherein A represents a C3 to C12 cycloalkyl group which may be substituted by one to three selected from a fluoro group, a hydroxy group, a C1 to C6 alkyl group, etc; R1, R2, and R3 each independently represent a hydrogen atom, a fluoro group, or a C1 to C6 alkyl group; R4 represents a hydrogen atom or a prodrug group; and Y represents —CH2—CHR5—CH2—NHR6 (wherein R5 represents a hydrogen atom, a C1 to C6 alkyl group, or a C1 to C6 alkoxy group, and R6 represents a hydrogen atom or a prodrug group), or the like exhibits excellent TAFIa inhibitory activity and is useful as a therapeutic drug for myocardial infarction, angina pectoris, acute coronary syndrome, cerebral infarction, deep vein thrombosis, pulmonary embolism, and the like.

Abstract: A compound represented by the following general formula (I) or a pharmacologically acceptable salt thereof, wherein A represents a C3 to C12 cycloalkyl group which may be substituted by one to three selected from a fluoro group, a hydroxy group, a C1 to C6 alkyl group, etc; R1, R2, and R3 each independently represent a hydrogen atom, a fluoro group, or a C1 to C6 alkyl group; R4 represents a hydrogen atom or a prodrug group; and Y represents —CH2—CHR5—CH2—NHR6 (wherein R5 represents a hydrogen atom, a C1 to C6 alkyl group, or a C1 to C6 alkoxy group, and R6 represents a hydrogen atom or a prodrug group), or the like exhibits excellent TAFIa inhibitory activity and is useful as a therapeutic drug for myocardial infarction, angina pectoris, acute coronary syndrome, cerebral infarction, deep vein thrombosis, pulmonary embolism, and the like.

Abstract: A compound represented by the following general formula (I) or a pharmacologically acceptable salt thereof, wherein A represents a C3 to C12 cycloalkyl group which may be substituted by one to three selected from a fluoro group, a hydroxy group, a C1 to C6 alkyl group, etc; R1, R2, and R3 each independently represent a hydrogen atom, a fluoro group, or a C1 to C6 alkyl group; R4 represents a hydrogen atom or a prodrug group; and Y represents —CH2—CHR5—CH2—NHR6 (wherein R5 represents a hydrogen atom, a C1 to C6 alkyl group, or a C1 to C6 alkoxy group, and R6 represents a hydrogen atom or a prodrug group), or the like exhibits excellent TAFIa inhibitory activity and is useful as a therapeutic drug for myocardial infarction, angina pectoris, acute coronary syndrome, cerebral infarction, deep vein thrombosis, pulmonary embolism, and the like.

Abstract: A compound represented by the following general formula (I) or a pharmacologically acceptable salt thereof, wherein A represents a C3 to C12 cycloalkyl group which may be substituted by one to three selected from a fluoro group, a hydroxy group, a C1 to C6 alkyl group, etc; R1, R2, and R3 each independently represent a hydrogen atom, a fluoro group, or a C1 to C6 alkyl group; R4 represents a hydrogen atom or a prodrug group; and Y represents —CH2—CHR5—CH2—NHR6 (wherein R5 represents a hydrogen atom, a C1 to C6 alkyl group, or a C1 to C6 alkoxy group, and R6 represents a hydrogen atom or a prodrug group), or the like exhibits excellent TAFIa inhibitory activity and is useful as a therapeutic drug for myocardial infarction, angina pectoris, acute coronary syndrome, cerebral infarction, deep vein thrombosis, pulmonary embolism, and the like.

Abstract: A compound represented by the following general formula (I) or a pharmacologically acceptable salt thereof, wherein R1 represents a C1 to C6 alkyl group which may be substituted by one to three groups selected from substituent group A, or the like (substituent group A: a hydroxy group, a halogeno group, a cyano group, a nitro group, an amino group, a carboxy group, a C1 to C3 alkyl group, etc.); R2, R3, and R8 each independently represent a hydrogen atom or a C1 to C3 alkyl group; R4, R5, R6, R7, R9, and R10 each independently represent a hydrogen atom or the like; and R11 represents a hydrogen atom or the like, has TAFIa enzyme inhibitory activity and is useful as a therapeutic drug for myocardial infarction, angina pectoris, acute coronary syndrome, cerebral infarction, deep vein thrombosis, pulmonary embolism, or the like.

Abstract: An object of the present invention is to provide a novel compound which has a potent inhibitory effect on FXa and exhibits an excellent antithrombotic effect when orally administered.

Abstract: A compound represented by the general formula (1): -Q1-Q2-T0-N(R1)-Q3-N(R2)-T1-Q4??(1) wherein R1 and R2 are hydrogen atoms or the like; Q1 is a saturated or unsaturated, 5- or 6-membered cyclic hydrocarbon group which may be substituted, or the like; Q2 is a single bond or the like; Q3 is a group in which Q5 is an alkylene group having 1 to 8 carbon atoms, or the like; and T0 and T1 are carbonyl groups or the like; a salt thereof, a solvate thereof, or an N-oxide thereof.

Abstract: The invention relates a compound represented by the formula (1): Q1-Q2-C(?O)—N(R1)-Q3-N(R2)-T1-Q4??(1) wherein R1 and R2 represent H or the like; Q1 represents an aromatic ring, heterocyclic ring or the like; Q2 represents a single bond, aromatic ring, heterocyclic ring or the like; Q3 represents a group or the like, Q4 represents an aromatic ring, heterocyclic ring or the like; and T1 represents —CO— or —SO2—, and a medicine which comprises the compound and is useful for thrombosis and embolism.

Abstract: The present invention relates to diamine compounds which inhibit activated blood coagulation factor X and exhibit an anticoagulant effect and there uses for treating various diseases based on thromboembolism.

Abstract: An image forming apparatus is provided having a mechanism that toner density of a toner image is automatically adjusted based on a toner patch. In an image forming apparatus including a document conveying section, a document reading section, an image forming section, a sheet discharging section, a sheet feeding section, a patch density detecting section, and a toner density adjusting section for adjusting density of a toner image depending on a result detected by the patch density detecting section, there are further provided a patch forming section for forming a toner patch, an operation detecting section for detecting an operating state of the patch density detecting section, and a patch printing section for printing the toner patch in response to such a result detected by the operation detecting section that the patch density detecting section does not properly operate, thereby adjusting the toner density based on the patch image.